Cambridge Investment Research Advisors, Inc. Halozyme Therapeutics, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.9 Billion
Q4 2024

A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 7,031 shares of HALO stock, worth $407,094. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,031

Previous 9,561 26.46%

Holding current value

$407,094

Previous $547,000 38.57%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$42.57 - $61.09 $107,702 - $154,557	-2,530 Reduced 26.46%	7,031 $336,000
Q3 2024 Oct 28, 2024	BUY	$51.3 - $64.42 $130,661 - $164,077	2,547 Added 36.31%	9,561 $547,000
Q2 2024 Jul 26, 2024	SELL	$37.81 - $52.4 $13,384 - $18,549	-354 Reduced 4.8%	7,014 $367,000
Q1 2024 Apr 24, 2024	SELL	$33.68 - $41.95 $23,508 - $29,281	-698 Reduced 8.65%	7,368 $300,000
Q4 2023 Feb 09, 2024	BUY	$33.32 - $42.1 $27,722 - $35,027	832 Added 11.5%	8,066 $298,000
Q3 2023 Oct 24, 2023	BUY	$36.46 - $44.03 $583 - $704	16 Added 0.22%	7,234 $276,000
Q2 2023 Jul 13, 2023	SELL	$30.28 - $38.74 $27,282 - $34,904	-901 Reduced 11.1%	7,218 $260,000
Q1 2023 May 11, 2023	SELL	$32.86 - $55.7 $11,698 - $19,829	-356 Reduced 4.2%	8,119 $310,000
Q4 2022 Feb 08, 2023	SELL	$40.06 - $59.44 $20,230 - $30,017	-505 Reduced 5.62%	8,475 $482,000
Q3 2022 Oct 17, 2022	BUY	$38.53 - $51.78 $46,929 - $63,068	1,218 Added 15.69%	8,980 $355,000
Q2 2022 Jul 13, 2022	BUY	$37.35 - $48.3 $7,470 - $9,660	200 Added 2.64%	7,762 $341,000
Q1 2022 May 12, 2022	SELL	$31.97 - $41.06 $11,892 - $15,274	-372 Reduced 4.69%	7,562 $301,000
Q4 2021 Feb 03, 2022	BUY	$31.82 - $40.75 $35,892 - $45,966	1,128 Added 16.57%	7,934 $319,000
Q3 2021 Nov 02, 2021	BUY	$38.47 - $46.42 $61,090 - $73,714	1,588 Added 30.43%	6,806 $276,000
Q2 2021 Aug 10, 2021	SELL	$38.84 - $51.31 $36,470 - $48,180	-939 Reduced 15.25%	5,218 $236,000
Q1 2021 May 07, 2021	BUY	$39.51 - $51.45 $908 - $1,183	23 Added 0.37%	6,157 $256,000
Q4 2020 Feb 04, 2021	BUY	$25.81 - $43.62 $158,318 - $267,565	6,134 New	6,134 $261,000
Q3 2020 Oct 29, 2020	SELL	$25.74 - $29.63 $242,856 - $279,559	-9,435 Closed	0 $0
Q2 2020 Jul 27, 2020	BUY	$16.25 - $26.81 $153,318 - $252,952	9,435 New	9,435 $252,000
Q1 2020 May 08, 2020	SELL	$13.9 - $21.83 $145,713 - $228,843	-10,483 Closed	0 $0
Q4 2019 Feb 04, 2020	SELL	$14.93 - $19.53 $1,478 - $1,933	-99 Reduced 0.94%	10,483 $185,000
Q3 2019 Nov 06, 2019	SELL	$15.2 - $17.69 $9,120 - $10,614	-600 Reduced 5.37%	10,582 $164,000
Q2 2019 Aug 15, 2019	SELL	$14.75 - $17.26 $7,375 - $8,630	-500 Reduced 4.28%	11,182 $0
Q1 2019 May 08, 2019	BUY	$13.94 - $17.58 $5,325 - $6,715	382 Added 3.38%	11,682 $0
Q3 2018 Nov 02, 2018	BUY	$16.68 - $18.41 $188,484 - $208,033	11,300 New	11,300 $0

Others Institutions Holding HALO

# of Institutions

545

Shares Held

124M

Call Options Held

668K

Put Options Held

259K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.06B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account

Cambridge Investment Research Advisors, Inc. Halozyme Therapeutics, Inc. Transaction History